NewslettersCell Therapy NewsResults from First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor with Calibrated Signaling in Large B-Cell LymphomaBy Noshin Noorjahan - January 31, 20250343In this first-in-human, Phase I, dose escalation and expansion clinical trial, patients with relapsed or refractory large B-cell lymphoma received 19(T2)28z-1XX CAR T cells at four dose levels.[Journal of Clinical Oncology]Abstract